Insmed, Inc. (INSM) Stock Ratings

View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:

Not Rated

No Current Ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
laurvp laurvp 09/21/2015 1 month $25.02 $17.12 -31.57% 31 Ended
Netteligent Netteligent 09/18/2015 1 month $25.80 $17.70 -31.4% 31 Ended
jad9000 jad9000 08/11/2015 3 months $26.54 $17.09 -35.61% -35 Ended
Comments: Exclusivity for150,000 NTM sufferers with $60,000 annual price. Expect MA approval in EU in 2016.
JOKER66 JOKER66 11/30/2012 1 day $7.59 $7.18 -5.4% 5 Ended
Unclebob9 Unclebob9 08/27/2011 3 months $4.45 $3.69 -17.08% -17 Ended
Comments: Upcoming product launch will be successful
xFD2x xFD2x 04/21/2010 3 months N/A Ended
Comments: Downwards risk seems limited to 93 cents.
countingch countingch 03/08/2010 3 months N/A Ended
Tariq_1 Tariq_1 03/02/2010 3 months N/A Ended
Comments: strong long... This company has a treatment for ALS and there are no other companies that have this.

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.